4D Molecular Therapeutics, Inc. reported $92M of revenue over the trailing twelve months, +278712% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $92M (to Q2 2026). Net income: −$179M, trailing twelve months to Q2 2026. Free cash flow: −$110M, trailing twelve months to Q4 2025. Operating margin: −18105%, trailing twelve months to Q2 2026.

FDMT4D Molecular Therapeutics, Inc.

Healthcare

$10.78+2.5% 1Y

$10.78

$7.1952 weeks$16.74

FDMT as reported

4D Molecular Therapeutics, Inc. reported $92M of revenue over the trailing twelve months, +278712% on the year before. 8 reported series are charted on this page, each one as filed.

$92M

Revenue, trailing twelve months · to Q2 2026 · +278712% against the twelve months before

Net income: −$179M
Net income · −8.7% year on year · trailing twelve months to Q2 2026
Free cash flow: −$110M
Free cash flow · trailing twelve months to Q4 2025
Operating margin: −18105%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for FDMT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$92M	+278712%	Q2 2026
Net income	−$179M	−8.7%	Q2 2026
EPS	−$2.63	−25%	Q2 2026
Operating margin	−18105%	n/a	Q2 2026
Net margin	−16840%	n/a	Q2 2026
ROE	−41%	n/a	Q2 2026
ROA	−35%	n/a	Q2 2026
Free cash flow	−$110M	n/a	Q4 2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.